BRD4 inhibition and FXR activation, individually beneficial in cholestasis, are antagonistic in combination

Activation of farnesoid X receptor (FXR) by obeticholic acid (OCA) reduces hepatic inflammation and fibrosis in patients with primary biliary cholangitis (PBC), a life-threatening cholestatic liver failure. Inhibition of bromodomain-containing protein 4 (BRD4) also has antiinflammatory, antifibrotic...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:JCI Insight
Hlavní autoři: Jung, Hyunkyung, Chen, Jinjing, Hu, Xiangming, Sun, Hao, Wu, Shwu-Yuan, Chiang, Cheng-Ming, Kemper, Byron, Chen, Lin-Feng, Kemper, Jongsook Kim
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society for Clinical Investigation 2020
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7821603/
https://ncbi.nlm.nih.gov/pubmed/33290278
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.141640
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky